Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Alzheimer's disease drug development and the problem of the blood‐brain barrier

Open access
Pardridge, William M.·2009·Alzheimer's & Dementia

Abstract

Alzheimer's disease (AD) drug development is limited by the presence of the blood‐brain barrier (BBB). More than 98% of all small‐molecule drugs, and ∼100% of all large‐molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present‐day AD drug‐development effort is characterized by an imbalance wherein >99% of the drug‐development effort is devoted to central nervous system (CNS) drug discovery, and <1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug‐targeting technology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2009.06.003

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 203

Metadata

Authors
Pardridge, W. M.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2009-09
Volume
5
Issue
5
Pages
427-432
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2052766986
Cited by
203
References
7
FWCI
4.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer's disease drug development and the problem of the blood‐brain barrier. https://app.cochat.ai/papers/10.1016/j.jalz.2009.06.003
The paper
Pardridge, W. M. (2009). Alzheimer's disease drug development and the problem of the blood‐brain barrier. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2009.06.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.